Adrian Wiestner

18.3k citations

231 papers · 9.5k indexed · 3 hit papers · h-index 52

Impact in

Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 187
- Chronic Lymphocytic Leukemia Research 185
Pathology and Forensic Medicine 124
- Lymphoma Diagnosis and Treatment 124

Co-authors: Louis M. Staudt Andreas Rosenwald Mohammed Farooqui Patricia Pérez‐Galán Jan A. Burger Sarah E. M. Herman Carsten Utoft Niemann Clare Sun
Journals: Blood (101 papers)Clinical Cancer Research (17 papers)Leukemia (7 papers)Cancer Research (7 papers)Journal of Clinical Oncology (7 papers)
Partner nations: United States Spain Netherlands

In The Last Decade

Adrian Wiestner

221 papers receiving 9.4k citations

Hit Papers

align trajectories log scale

Targeting B cell receptor signalling in cancer: preclinical and clinical advances 2018 · 296 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature reviews. Cancer
2003 Proceedings of the National Academy of Sciences
2003 Blood

Peers

Countries citing papers authored by Adrian Wiestner

Since Specialization

Citations

This map shows the geographic impact of Adrian Wiestner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Wiestner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Wiestner more than expected).

Fields of papers citing papers by Adrian Wiestner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Wiestner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Wiestner. The network helps show where Adrian Wiestner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Adrian Wiestner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adrian Wiestner Line = papers co-authored together Adrian Wiestner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study Blood ·С. Ю. Таскаев, Fikrat Abdul-Kareem Fattah, Zheng Jie-jing, Constance M. Yuan, Hao‐Wei Wang, Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Clare Sun, Nataliia MAKOHONCHUK, Susan Soto, Jeanine Superata, RAQUEL VASCONCELOS DE SALES, Thomas E. Hughes, Pia Nierman, Adrian Wiestner	2025	0
2	Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib Clinical Cancer Research ·敦浩中本, Jean Cheung, Michael Gulrajani, Erika M. Gaglione, Pia Nierman, Ahmed Hamdy, Raquel Izumi, Елена Бибикова, Priti Patel, Clare Sun, Todd Covey, Sarah E.M. Herman, Adrian Wiestner	2020	21
3	IKAP—Identifying K mAjor cell Population groups in single-cell RNA-sequencing analysis GigaScience ·H-C Flemming, James Geiss, Chingiz Underbayev, Clare Sun, Komudi Singh, Fayaz Seifuddin, Adrian Wiestner, Mehdi Pirooznia	2019	13
4	TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib Cancer Research ·Eman L. Dadashian, Erin M. McAuley, Delong Liu, Arthur L. Shaffer, Ryan M. Young, M. Romero de la Osa, Michael J. Kruhlak, Louis M. Staudt, Adrian Wiestner, Sarah E. M. Herman	2018	44
5	Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1 Proceedings of the National Academy of Sciences ·Junpeng Qi, Xiuling Li, Haiyong Peng, Erika M. Cook, Eman L. Dadashian, Adrian Wiestner, HaJeung Park, Christoph Rader	2018	62
6	Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model Clinical Cancer Research ·Carsten Utoft Niemann, Helena Mora-Jensen, Eman L. Dadashian, Fanny Krantz, Todd Covey, Shih‐Shih Chen, Nicholas Chiorazzi, Raquel Izumi, Roger G. Ulrich, Brian J. Lannutti, Adrian Wiestner, Sarah E. M. Herman	2017	25
7	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia Cancer Research ·Nakhle S. Saba, Deanna H. Wong, Hanxing Lin, M. Romero de la Osa, Patricia Lobelle‐Rich, Eman L. Dadashian, Delong Liu, Lorena Fontán, Erik K. Flemington, Cydney Nichols, Chingiz Underbayev, Hana Safah, Ari Melnick, Adrian Wiestner, Sarah E. M. Herman	2017	40
8	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia Clinical Cancer Research ·Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger G. Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach	2016	121
9	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia Clinical Cancer Research ·Alba Matas‐Céspedes, 美英子山口, Vanina Rodríguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo Menéndez, Elı́as Campo, Armando López‐Guillermo, Dolors Colomer, Gaël Roué, Adrian Wiestner, Paul W.H.I. Parren, Parul Doshi, Jeroen Lammerts van Bueren, Patricia Pérez‐Galán	2016	45
10	Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma Blood ·Nakhle S. Saba, Delong Liu, Sarah E. M. Herman, Chingiz Underbayev, Xin Tian, 幸子矢代, Marc A. Weniger, Martin Skarzynski, Pineda Pena AC, Lorena Fontán, Ari Melnick, Clíona Grant, Mark Roschewski, Alba Navarro, Sı́lvia Beà, Stefania Pittaluga, Kieron Dunleavy, Wyndham H. Wilson, Adrian Wiestner	2016	111
11	Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo Clinical Cancer Research ·Sarah E. M. Herman, Rashida Z. Mustafa, Jade Jones, Deanna H. Wong, Mohammed Farooqui, Adrian Wiestner	2015	91
12	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study Clinical Cancer Research ·Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić, Julio Gómez‐Rodríguez, Angélique Biancotto, Betty Chang, Sabrina Martyr, Maryalice Stetler‐Stevenson, Constance M. Yuan, Katherine R. Calvo, Raul C. Braylan, Janet Valdez, Yuh Shan Lee, Deanna H. Wong, Jade Jones, Clare Sun, Gerald E. Marti, Mohammed Farooqui, Adrian Wiestner	2015	160
13	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy Clinical Cancer Research ·Martin Skarzynski, Carsten Utoft Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Marić, Dalia Salem, Maryalice Stetler‐Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance M. Yuan, Janet Valdez, Susan Soto, Mohammed Farooqui, Sarah E. M. Herman, Adrian Wiestner	2015	62
14	Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia Cancer Research ·Bérengère Vire, Martin Skarzynski, Joshua D. Thomas, Indradesman Telaumbanua, Alexandre David, Georg Aue, Terrence R. Burke, Christoph Rader, Adrian Wiestner	2014	12
15	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia Cancer Research ·Warren Fiskus, Nakhle S. Saba, Min Shen, Mondana Ghias, Jinyun Liu, Soumyasri Das Gupta, Lata Chauhan, Rekha Rao, Sumedha Gunewardena, F. Ferrere, Christopher P. Austin, Kami J. Maddocks, John C. Byrd, Ari Melnick, Peng Huang, Adrian Wiestner, Kapil N. Bhalla	2014	198
16	Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients Blood ·Betty Chang, Michelle Francesco, Martin F. M. de Rooij, Padmaja Magadala, Susanne Steggerda, Min Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham H. Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias	2013	159
17	microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics Clinical Cancer Research ·Alba Navarro, Guillem Clot, Hikaru ・・・・・・, Cristina Royo, Maria Carmela Vegliante, Virginia Amador, Elena Hartmann, Itziar Salaverría, Sı́lvia Beà, José I. Martı́n-Subero, Andreas Rosenwald, German Ott, Adrian Wiestner, Wyndham H. Wilson, Elı́as Campo, Luís Hernández	2013	29
18	ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress Clinical Cancer Research ·淳二高柳, Ellen X. Sun, Mark Roschewski, Georg Aue, A. Duma-Copcea, Lawrence Stennett, Federica Gibellini, Diane C. Arthur, Patricia Pérez‐Galán, Adrian Wiestner	2012	61
19	Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma Clinical Cancer Research ·Marc A. Weniger, Edgar Gil Rizzatti, Patricia Pérez‐Galán, Delong Liu, Qiuyan Wang, Peter J. Munson, Nalini Raghavachari, Therese White, Nigussie Gezehagn, Kieron Dunleavy, Yihong Ye, Wyndham H. Wilson, Adrian Wiestner	2011	82
20	Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines Clinical Cancer Research ·Ana I. Robles, Mollie H. Wright, 啓天田, A.T. Kulyasov, Christin L. Hanigan, Adrian Wiestner, Lyuba Varticovski	2006	30

About Adrian Wiestner

Adrian Wiestner is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 231 papers that have together received 9.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (185 papers), Lymphoma Diagnosis and Treatment (124 papers), Immunodeficiency and Autoimmune Disorders (47 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Chronic Myeloid Leukemia Treatments (29 papers), CAR-T cell therapy research (14 papers), Ubiquitin and proteasome pathways (13 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). The work is most often cited by research in Genetics (5.5k citations), Pathology and Forensic Medicine (4.6k citations), Hematology (1.8k citations), Immunology (3.1k citations) and Oncology (2.3k citations). Adrian Wiestner has collaborated with scholars based in United States, Spain and Netherlands. Frequent co-authors include Louis M. Staudt, Andreas Rosenwald, Mohammed Farooqui, Patricia Pérez‐Galán, Jan A. Burger, Sarah E. M. Herman, Carsten Utoft Niemann, Clare Sun, George W. Wright and Bruce K. Tan. Their work appears in journals such as Blood, Clinical Cancer Research, Leukemia, Cancer Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact